Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SciSparc Ltd. ( (SPRC) ) has shared an announcement.
On November 20, 2025, SciSparc Ltd. announced that NeuroThera Labs Inc., in collaboration with Clearmind Medicine Inc., has filed an Israeli patent application for a new non-hallucinogenic neuroplastogen treatment for depression. This filing is part of an ongoing effort to expand their intellectual property portfolio, which includes 13 patents aimed at addressing various conditions such as addiction and obesity. The development of this innovative therapy could significantly impact the treatment of depression, a condition affecting over 332 million people globally, and enhance SciSparc’s position in the pharmaceutical industry.
More about SciSparc Ltd.
SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders through its majority-owned subsidiary, Neurothera Labs Inc. The company specializes in cannabinoid pharmaceuticals and is involved in drug development programs targeting conditions like Tourette syndrome, Alzheimer’s disease, and autism spectrum disorder.
Average Trading Volume: 4,713,397
Technical Sentiment Signal: Sell
Current Market Cap: $3.99M
Learn more about SPRC stock on TipRanks’ Stock Analysis page.